Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to 1475.59%.

  • TScan Therapeutics' EBITDA Margin rose 16342300.0% to 1475.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 1765.01%, marking a year-over-year decrease of 4889400.0%. This contributed to the annual value of 4525.85% for FY2024, which is 41019900.0% down from last year.
  • As of Q3 2025, TScan Therapeutics' EBITDA Margin stood at 1475.59%, which was up 16342300.0% from 1256.6% recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' EBITDA Margin registered a high of 296.17% during Q4 2023, and its lowest value of 6364.55% during Q2 2024.
  • For the 5-year period, TScan Therapeutics' EBITDA Margin averaged around 1630.16%, with its median value being 636.69% (2023).
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -55827900bps in 2024, then skyrocketed by 51079500bps in 2025.
  • Over the past 5 years, TScan Therapeutics' EBITDA Margin (Quarter) stood at 497.62% in 2021, then fell by -21bps to 602.55% in 2022, then skyrocketed by 51bps to 296.17% in 2023, then tumbled by -1764bps to 5520.6% in 2024, then soared by 73bps to 1475.59% in 2025.
  • Its EBITDA Margin was 1475.59% in Q3 2025, compared to 1256.6% in Q2 2025 and 1669.74% in Q1 2025.